Efficacy and safety of gemigliptin as add‐on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study)-Reference-Cited by-同舟云学术

Efficacy and safety of gemigliptin as add‐on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study)

Published:2019-10-08 Issue:1 Volume:22 Page:123-127
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Cho Young Min¹^ORCID,Deerochanawong Chaicharn²^ORCID,Seekaew Samroeng³,Suraamornkul Swangjit⁴,Benjachareonwong Sunun⁵,Sattanon Sarinya⁶,Chamnan Parinya⁷,Sirirak Thanitha⁸,Kosachunhanun Natapong⁹,Pratipanawatr Thongchai¹⁰,Suwanwalaikorn Sompongse¹¹,Lee Woo Je¹²^ORCID,Kim Sungrae¹³,Choi Seonghui¹⁴,Kang Eun Seok¹⁵^ORCID,Oh Taekeun¹⁶,Kwon Sam¹⁷,Lee Moon‐Kyu¹⁸^ORCID

Affiliation:

1. Department of Internal MedicineSeoul National University College of Medicine Seoul South Korea

2. Diabetes and Endocrinology UnitRajavithi Hospital, Rangsit University College of Medicine Bangkok Thailand

3. Chiangrai Prachanukroh Hospital Chiang Rai Thailand

4. Vajira Hospital, Faculty of MedicineNavamindradhiraj University Bangkok Thailand

5. Police General Hospital Bangkok Thailand

6. Naresuan University Hospital Phitsanulok Thailand

7. Cardiometabolic Research Group, Department of Social MedicineSanpasitthiprasong Hospital Ubon Ratchathani Thailand

8. Department of Family Medicine and Preventive Medicine, Faculty of MedicinePrince of Songkla University Hat Yai, Songkhla Thailand

9. Maharaj Nakorn Chiang Mai Hospital Chiang Mai Thailand

10. Faculty of MedicineKhon Kaen University Khon Kaen Thailand

11. Division of Endocrinology and Metabolism, Department of Medicine, Faculty of MedicineChulalongkorn University Bangkok Thailand

12. Department of Internal MedicineUniversity of Ulsan College of Medicine Seoul South Korea

13. Division of Endocrinology and MetabolismCatholic University of Korea Seoul South Korea

14. Department of MedicineSeoul National University Bundang Hospital, Seoul National University College of Medicine Seoul South Korea

15. Department of Internal MedicineSeverance Hospital, Yonsei University College of Medicine Seoul South Korea

16. Chungbuk National University Hospital, Chungbuk National University College of Medicine Chungbuk Cheongju, South Korea

17. Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon South Korea

18. Division of Endocrinology and Metabolism, Department of MedicineSamsung Medical Center, Sungkyunkwan University School of Medicine Seoul South Korea

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13873

Reference13 articles.

1. Challenges Associated with Insulin Therapy in Type 2 Diabetes Mellitus

2. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

4. Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

5. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION);Endocrinology and Metabolism;2023-06-30

2. Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition;Acta Pharmaceutica Sinica B;2022-11

3. Sojourn of Gemigliptin: A Hidden Gem?;Clinical Diabetology;2022-06-30

4. Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system;Scientific Reports;2021-10-22

5. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors;Current Drug Safety;2021-06-08